

PRESSRELEASE

OptiCell Solutions AB announce the addition of Dr. Ulla Axdorph Nygell as the Medically Responsible Person. Huddinge, Sweden 2024-11-04

OptiCell Solutions AB is delighted to announce the addition of Dr. Ulla Axdorph Nygell to our team as the Medically Responsible Person. Dr. Axdorph Nygell brings invaluable experience and expertise that will be pivotal as we advance in the field of apheresis and cell collection for cell and gene therapy.

Dr. Axdorph Nygell, MD, PhD, is a Specialist in Internal Medicine, Hematology/Transfusion Medicine, and an Associate Professor at Karolinska Institute. She joins us with over two decades of dedicated experience as the Medical Director at the Apheresis Unit of Clinical Immunology/Transfusion Medicine at Karolinska University Hospital. Her responsibilities have spanned patient-donor related apheresis, stem cell donor evaluation, and management, showcasing her commitment to advancing medical care in this field.

In addition to her clinical role, Dr. Axdorph Nygell has served as the Medical Director for the Tobias Registry and contributed her expertise to the Ethics Working Group of the World Marrow Donor Association. Her extensive involvement with various industry stakeholders as a responsible investigator highlights her dedication to innovative research and collaboration within the field. She is also a longstanding member of the Swedish Apheresis Association ([Svensk AferesGrupp, SAG](#)) and has played significant roles in national health organizations, including the National Board of Health and Welfare ([Socialstyrelsen](#)) and the Swedish Medical Products Agency ([Läkemedelsverket](#)), as the Responsible Physician for Clinical Immunology/Transfusion Medicine.

"We are thrilled to have Ulla join our team," said Jarmo Henriksson, CEO of OptiCell Solutions AB. "Her wealth of knowledge and her commitment to advancing apheresis and transfusion medicine will be instrumental in driving OptiCell Solutions' mission to provide high-quality, patient-centered services for cell and gene therapy."

Dr. Axdorph Nygell's expertise in both clinical and research environments strengthens our capabilities to deliver cutting-edge solutions in cellular therapy. Her commitment to ethics and quality aligns perfectly with our mission to enhance patient care and safety.

--- END PRESSRELEASE---

For more information, please contact

General Manager, Jarmo Henriksson, +46 (0) 73 699 48 37, jarmo.henriksson@opticellsolutions.com
Chairman of the board, Peter Rybäck, +46 (0) 73 849 07 96, peter.ryback@opticellsolutions.com

About OptiCell Solutions

Founded in 2024, OptiCell Solutions AB specializing in the field of apheresis and cell collection for cell and gene therapy (CAGT). By using our advanced apheresis technology, we can collect large quantities of specific donor cells, significantly advancing CAGT applications within in the biotech and healthcare sector. Furthermore, our extensive experience and know-how in apheresis enable us to offer specialized therapeutic apheresis services to the healthcare sector.

Located near the Karolinska University Hospital in Huddinge we aim to bridge the gap in resources by offering innovative solutions that enhance the availability of essential cells for cutting-edge research and life-saving therapies. With our deep expertise in apheresis technology and a strong commitment to ethical research practices, we are dedicated to improving patient outcomes and supporting the development of next-generation therapies for cancer care, autoimmune diseases, and other severe medical conditions.

At OptiCell Solutions, we strive to be at the forefront of medical innovation, providing the tools and services necessary to accelerate the transition to more effective and patient-centred care. For more information visit our website, www.opticellsolutions.com and follow us at [LinkedIn](#).